AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19347696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) adaptation of the Coping with Stress program, duration not specified.
Number of subjects: 0
Study 19347696 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 19347696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 16626410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1000
Study 16626410 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1000
Study 15518064 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix B (37 persons)
Number of subjects: 72
Study 15518064 — intervention group
Group type: COMPARATOR
Intervention: Twinrix (35 persons)
Number of subjects: 72
Study 15518064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 72
Study 10910900 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand (FL) administration
Number of subjects: 0
Study 9308064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg.kg‐1
Number of subjects: 43
Study 9308064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg.kg‐1
Number of subjects: 43
Study 9308064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8467623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (400 mg orally with food twice a day)
Number of subjects: 371
Study 8467623 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg orally, fasting, three times a day)
Number of subjects: 371
Study 31189279 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode light phototherapy
Number of subjects: 460
Study 31189279 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent light phototherapy
Number of subjects: 460
Study 28675116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol infusion
Number of subjects: 51
Study 28675116 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 51
Study 24077127 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression stockings (18 mm of Hg)
Number of subjects: 24
Study 24077127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner sole
Number of subjects: 24
Study 24077127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments together
Number of subjects: 24
Study 24077127 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 22790511 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (n=25)
Number of subjects: 50
Study 22790511 — intervention group
Group type: COMPARATOR
Intervention: Men (n=25)
Number of subjects: 50
Study 21972403 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedure and postprocedure hydration of sodium bicarbonate (early hydration group)
Number of subjects: 450
Study 21972403 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure hydration of isotonic saline (late hydration group)
Number of subjects: 450
Study 21972403 — intervention group
Group type: COMPARATOR
Intervention: No hydration (control group)
Number of subjects: 450
Study 19928484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (experimental)
Number of subjects: 117
Study 19928484 — intervention group
Group type: COMPARATOR
Intervention: Injury prevention (control)
Number of subjects: 117
Study 16467022 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily (standard regimen)
Number of subjects: 2005
Study 16467022 — intervention group
Group type: COMPARATOR
Intervention: Intermittent terbinafine 350 mg daily for 2 weeks on, 2 weeks off
Number of subjects: 2005
Study 15221928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 3600
Study 15221928 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion lymphadenectomy
Number of subjects: 3600
Study 15221928 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular staging
Number of subjects: 3600
Study 15221928 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapeutic lymphadenectomy and adjuvant interferon alfa‐2b therapy
Number of subjects: 3600
Study 11534891 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol used as needed
Number of subjects: 0
Study 11534891 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of formoterol
Number of subjects: 0
Study 11534891 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing of formoterol
Number of subjects: 0
Study 11534891 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol for acute asthma attacks
Number of subjects: 0
Study 9296944 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hypertension group (35 women)
Number of subjects: 65
Study 9296944 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy women)
Number of subjects: 65
Study 8422839 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-injection regimen (regular prebreakfast, regular prelunch, and [regular+ultralente] predinner)
Number of subjects: 205
Study 8422839 — intervention group
Group type: COMPARATOR
Intervention: Two-injection regimen ([regular+intermediary] prebreakfast and predinner)
Number of subjects: 205
Study 8422839 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-injection regimen
Number of subjects: 205
Study 8422839 — intervention group
Group type: COMPARATOR
Intervention: Three-injection regimen and Two-injection regimen
Number of subjects: 205
Study 3788652 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 32
Study 3788652 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol decanoate
Number of subjects: 32
Study 30281183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 12
Study 30281183 — intervention group
Group type: COMPARATOR
Intervention: MI Varnish application
Number of subjects: 12
Study 27577546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 25
Study 27577546 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 25
Study 25240121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (t-VNS) in the Ramsay-Hunt zone
Number of subjects: 60
Study 25240121 — intervention group
Group type: COMPARATOR
Intervention: Earlobe stimulation (control group)
Number of subjects: 60
Study 25240121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (t-VNS and control)
Number of subjects: 60
Study 22333561 — intervention group
Group type: EXPERIMENTAL
Intervention: FARES method
Number of subjects: 160
Study 22333561 — intervention group
Group type: COMPARATOR
Intervention: Eachempati external rotation method
Number of subjects: 160
Study 20595309 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical display (sparklines)
Number of subjects: 12
Study 20595309 — intervention group
Group type: COMPARATOR
Intervention: Conventional table display
Number of subjects: 12
Study 18520178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with cedar pollen extract
Number of subjects: 0
Study 18520178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypress pollen specific IgE antibodies
Number of subjects: 0
Study 16870050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 10
Study 14504627 — intervention group
Group type: EXPERIMENTAL
Intervention: High group (individual face-to-face counselling up to 1 hour monthly for 1 year)
Number of subjects: 212
Study 14504627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low group (one face-to-face individual counselling session, then monthly telephone contacts for 1 year)
Number of subjects: 212
Study 14504627 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 212
Study 10781855 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC
Number of subjects: 182
Study 10781855 — intervention group
Group type: COMPARATOR
Intervention: MenPS
Number of subjects: 182
Study 8899756 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline flush (2.5 ml, 100 U/ml)
Number of subjects: 51
Study 8899756 — intervention group
Group type: COMPARATOR
Intervention: Normal saline flush (5 ml)
Number of subjects: 51
Study 1999942 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 1999942 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study 6846212 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% fructose diet
Number of subjects: 24
Study 6846212 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% fructose diet
Number of subjects: 24
Study 6846212 — intervention group
Group type: COMPARATOR
Intervention: 0% fructose diet
Number of subjects: 24
Study 6846212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose diets (7.5% and 15%)
Number of subjects: 24
Study 6846212 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal insulin responses)
Number of subjects: 24
Study 30540689 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive intervention (percutaneous transluminal cerebral angioplasty and stenting)
Number of subjects: 70
Study 30540689 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous thrombolysis with urokinase)
Number of subjects: 70
Study 30540689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 30184455 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir (40 or 80 mg)
Number of subjects: 1064
Study 30184455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064
Study 30184455 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (75 mg twice daily for 5 days)
Number of subjects: 1064
Study 30184455 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 1064
Study 30184455 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 1064
Study 27596224 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF) intervention
Number of subjects: 54085
Study 27596224 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54085
Study 24999213 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan (20 mg intravenously)
Number of subjects: 116
Study 24999213 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 116
Study 22173517 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with oral gentamicin (80 mg 4 times per day) and oral polymyxin E gel (0.5 g 4 times per day) for 7 days
Number of subjects: 40
Study 22173517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo gel and 2 placebo oral solutions 4 times per day for 7 days)
Number of subjects: 40
Study 20350641 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) in no-cerclage group
Number of subjects: 300
Study 20350641 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) in cerclage group
Number of subjects: 300
Study 20350641 — intervention group
Group type: COMPARATOR
Intervention: Control (no 17P) in cerclage group
Number of subjects: 300
Study 20350641 — intervention group
Group type: COMPARATOR
Intervention: Control (no 17P) in no-cerclage group
Number of subjects: 300
Study 17685705 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TRN; n = 8)
Number of subjects: 17
Study 17685705 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL; n = 9)
Number of subjects: 17
Study 21359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Latino version of the curriculum
Number of subjects: 3402
Study 21359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicultural version of the curriculum
Number of subjects: 3402
Study 21359122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3402
Study 12435472 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 95
Study 12435472 — intervention group
Group type: COMPARATOR
Intervention: Placebo blockade (saline)
Number of subjects: 95
Study 12435472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups analysis
Number of subjects: 95
Study 12435472 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DBP in LBP subjects
Number of subjects: 95
Study 10352387 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + transdermal estrogen
Number of subjects: 0
Study 10352387 — intervention group
Group type: COMPARATOR
Intervention: CC only
Number of subjects: 0
Study 8687263 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders printed on daily rounds reports about preventive care for which their patients were eligible.
Number of subjects: 78
Study 8687263 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 78
Study 1901071 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine predischarge coronary arteriography (routine catheterization group)
Number of subjects: 1658
Study 1901071 — intervention group
Group type: COMPARATOR
Intervention: Selective predischarge coronary arteriography (selective catheterization group)
Number of subjects: 1658
Study 6138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blockade)
Number of subjects: 0
Study 31721503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast expansion
Number of subjects: 40
Study 31721503 — intervention group
Group type: COMPARATOR
Intervention: Slow expansion
Number of subjects: 40
Study 28393258 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (noninvasive ventilation) for the first 48 hours after extubation
Number of subjects: 144
Study 28393258 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen treatment (usual care)
Number of subjects: 144
Study 25418079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 21
Study 25418079 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotène(®) mouthwash Oral Rinse
Number of subjects: 21
Study 25418079 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 21
Study 25418079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin vs Biotène(®) mouthwash
Number of subjects: 21
Study 25418079 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotène(®) mouthwash adherence
Number of subjects: 21
Study 24461526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (1,500 IU) and Vitamin D (500 IU) supplementation for 3 months
Number of subjects: 597
Study 24461526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 597
Study 22526411 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 250 mg
Number of subjects: 65
Study 22526411 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 500 mg
Number of subjects: 65
Study 22526411 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 750 mg
Number of subjects: 65
Study 22526411 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg
Number of subjects: 65
Study 19400438 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual illusion of having two right arms
Number of subjects: 0
Study 17679311 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0
Study 15221178 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with body-weight support for 1.5-3 months
Number of subjects: 6
Study 15221178 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward stepping training for 2-3 weeks
Number of subjects: 6
Study 15221178 — intervention group
Group type: COMPARATOR
Intervention: Untrained backward stepping on treadmill
Number of subjects: 6
Study 15221178 — intervention group
Group type: COMPARATOR
Intervention: Untrained stepping in place on idle treadmill
Number of subjects: 6
Study 11787914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Number of subjects: 55
Study 11787914 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Number of subjects: 55
Study 9422305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 1.4 mg x kg(‐1)
Number of subjects: 10
Study 9422305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg x kg(‐1)
Number of subjects: 10
Study 9422305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 1.1 mg x kg(‐1)
Number of subjects: 10
Study 8230896 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlexanox
Number of subjects: 15
Study 8230896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study 2984397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (1 gm/kg over 12 hours, every other day)
Number of subjects: 0
Study 2984397 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 0
Study 31248404 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive lifestyle modification programme
Number of subjects: 0
Study 31248404 — intervention group
Group type: COMPARATOR
Intervention: Less intensive lifestyle modification programme
Number of subjects: 0
Study 29227578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus exenatide
Number of subjects: 0
Study 29227578 — intervention group
Group type: COMPARATOR
Intervention: Basal/bolus insulin therapy
Number of subjects: 0
Study 25751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative & Proactive Solutions (CPS)
Number of subjects: 134
Study 25751000 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 134
Study 25751000 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 134
Study 24315894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13455
Study 24315894 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13455
Study 24315894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 13455
Study 24339687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea symbols
Number of subjects: 47
Study 24339687 — intervention group
Group type: COMPARATOR
Intervention: Bailey-Lovie tumbling E chart
Number of subjects: 47
Study 24339687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-eye differences
Number of subjects: 47
Study 20544158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needle stimulation to a right supraspinatus trigger point (C4,5)
Number of subjects: 40
Study 20544158 — intervention group
Group type: COMPARATOR
Intervention: Sham intramuscular dry needle puncture (Control)
Number of subjects: 40
Study 18793221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrafiltration)
Number of subjects: 35
Study 18793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration with constant flow of 300 mL/m²/min and filtrate volume of 3000 mL
Number of subjects: 35
Study 18793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis added to hemofiltration
Number of subjects: 35
Study 18793221 — intervention group
Group type: EXPERIMENTAL
Intervention: Other filtration strategies (not specified)
Number of subjects: 35
Study 16472379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 0
Study 16472379 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative lumbar manipulation technique
Number of subjects: 0
Study 16472379 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thrust lumbar mobilization technique
Number of subjects: 0
Study 12787969 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (conjugated equine estrogens 0.625 mg)
Number of subjects: 121
Study 12787969 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 121
Study 12787969 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 121
Study 12787969 — intervention group
Group type: COMPARATOR
Intervention: Control group (women who declined or did not qualify for treatment)
Number of subjects: 121
Study 10951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (4 mg kg‐1 daily for 4 weeks)
Number of subjects: 30
Study 10951147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 10951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label cyclosporin (after randomized trial)
Number of subjects: 30
Study 10951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 30
Study 8838437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (100 mg)
Number of subjects: 20
Study 8838437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (200 mg)
Number of subjects: 20
Study 8838437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (100 mg and 200 mg)
Number of subjects: 20
Study 8838437 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release tramadol
Number of subjects: 20
Study 1468244 — intervention group
Group type: EXPERIMENTAL
Intervention: CR dihydrocodeine (60 mg) tablets (1 tablet twice daily to 2 tablets daily)
Number of subjects: 86
Study 1468244 — intervention group
Group type: COMPARATOR
Intervention: Combination dextropropoxyphene (32.5 mg)/paracetamol (325 mg) tablets (2 tablets 3‐times daily to 2 tablets 4‐times daily)
Number of subjects: 86
Study 6988959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Ventilation (IMV)
Number of subjects: 36
Study 30905495 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Motion Extension (RME) program
Number of subjects: 42
Study 30905495 — intervention group
Group type: COMPARATOR
Intervention: Controlled Active Motion (CAM) program
Number of subjects: 42
Study 29957886 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 85